Some patients taking oral formulations report slightly increased upper gastrointestinal symptoms including heartburn or stomach discomfort compared to injectable forms, potentially related to local gastric effects before absorption
In the phase 3 SLIMMER trial published in The Lancet Diabetes & Endocrinology last year, ecnoglutide achieved weight loss of 15.1% at 48 weeks, with no evidence of a plateauing of effect, along with improvements in waist circumference, blood pressure, lipid profile, HbA1c, fasting glucose, and insulin levels
If you reach 4 mg and are losing 2 pounds per week consistently with minimal side effects, staying at 4 mg is a perfectly valid choice
healthcare providers and compounding pharmacies, giving patients a safer alternative to unregulated overseas sources
Amino acids are used to make different types of proteins that are foundational to life itself
GLP-1 and Inflammation in Endometriosis One of the most compelling reasons GLP-1 medications are being discussed in endometriosis is their effect on systemic inflammation and immune signaling